Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2658-2663

  Matsumura, Noriomi ^a   Mandai, Masaki ^a   Okamoto, Takako ^a   Yamaguchi, Ken ^a,b   Yamamura, Shogo ^a   Oura, Tomonori ^c   Baba, Tsukasa ^a   Hamanishi, Junzo ^a   Kang, Hyun S ^a   Matsui, Shigeyuki ^d   Mori, Seiichi ^e   Murphy, Susan K ^b   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^d INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HEPATOCYTE NUCLEAR FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RAS PROTEIN; SORAFENIB; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CLEAR CELL CARCINOMA; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78449305340     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01736.x     Document Type: Article

References (34)

1. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002; 95: 2380-9.
2. Skírnisdóttir I, Seidal T, Karlsson MG, Sorbe B. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005; 26: 177-83.
3. Parker TM, Dockerty MB, Randall LM. Mesonephric clear cell carcinoma of the ovary: a clinical and pathologic study. Am J Obstet Gynecol 1960; 80: 417-25.
4. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008; 99: 653-8.
5. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
6. Winter WE, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 20: 3621-7.
7. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006; 6: 735-41.
8. Yamaguchi K, Mandai M, Oura T et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010; doi:.
9. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7.
10. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-44.
11. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-27.
12. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
13. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-28.
14. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 5601-8.
15. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-45.
16. Igarashi P, Shao X, McNally BT, Hiesberger T. Roles of HNF-1beta in kidney development and congenital cystic diseases. Kidney Int 2005; 68: 1944-7.
17. Gresh L, Fischer E, Reimann A et al. A transcriptional network in polycystic kidney disease. EMBO J 2004; 23: 1657-68.
18. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003; 163: 2503-12.
19. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
20. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 2007; 106: 311-17.
21. Miyazawa M, Yasuda M, Fujita M et al. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 2009; 59: 19-27.
22. Simsir A, Palacios D, Linehan WM, Merino MJ, Abati A. Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: utilization of microdissection and polymerase chain reaction in archival tissues. Diagn Cytopathol 2001; 24: 328-32.
23. Yamamoto S, Tsuda H, Suzuki K, Takano M, Tamai S, Matsubara O. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Arch 2009; 455: 261-70.
24. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-90.
25. Berchuck A, Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997; 54: 541-4.
26. Berchuck A. Biomarkers in the ovary. J Cell Biochem 1995; 23: 223-6.
27. Iba T, Kigawa J, Kanamori Y et al. Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 2004; 95: 418-23.
28. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991; 139: 777-85.
29. Gemignani ML, Schlaerth AC, Bogomolniy F et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-81.
30. Mayr D, Hirschmann A, Löhrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-7.
31. Ma Z, Gong Y, Patel V et al. Mutations of HNF-1beta inhibit epithelial morphogenesis through dysregulation of SOCS-3. Proc Natl Acad Sci USA 2007; 104: 20386-91.
32. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006; 12: 7215-20.
33. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
34. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9: 167-81.